MDSO News Alert Medidata Solutions (MDSO) 47.27 12/25/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medidata Solutions (MDSO) 47.27 $MDSO

Cramer's Mad Money - Navigator Holdings Has Been Unfairly Punished (12/23/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 24, 4:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday December 23. Navigator Holdings (NYSE: NVGS ) Has Been Unfairly Punished . Other stock mentioned: Transocean (NYSE: RIG ) With the surge in stocks, it...
RH: 96.97 (-0.16), GD: 141.54 (+0.23), LMT: 196.43 (+0.66), HON: 101.96 (-0.02), RTN: 110.47 (+0.29), NOC: 151.76 (+0.44), KMB: 117.77 (-0.21), XOM: 93.78 (-0.81), IBB: 299.80 (+5.12), VSAT: 63.75 (-0.20), NVGS: 20.00 (+2.10), JACK: 78.82 (-0.17), RIG: 18.77 (-0.37), Q: 59.48 (+0.01), COST: 143.65 (-0.50), WAG: 76.67 (+0.16), ETN: 69.30 (-0.09), MDSO: 47.27 (+0.15), DIS: 94.42 (-0.27), WFC: 55.34 (-0.13), PLKI: 55.50 (+0.01), BA: 131.24 (+1.21), DENN: 9.96 (+0.05), CBRL: 138.16 (+0.46), GILD: 91.29 (+1.84), CVX: 113.47 (-0.48)

Medidata Announces Availability of Patient Profiles Offering
Business Wire - Wed Dec 10, 7:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the availability of its enriched solution for risk-based monitoring (RBM) of clinical trial sites. The company's previously announced acquisition of Patient Profiles, an early-stage software company focused on improving clinical trial data quality, broadens Medidata's best-in-class technology for RBM, a proven methodology for reducing trial costs while providing a higher level of clinical data accuracy and quality.
MDSO: 47.27 (+0.15)

Vital Connect Partners with Medidata to Enhance Clinical Trials with Continuous Vital Sign Monitoring
Business Wire - Tue Dec 09, 11:00AM CST
Vital Connect announced today that its FDA-cleared wearable biosensor, HealthPatch(R) MD, is now available for use in clinical trials in partnership with Medidata (NASDAQ: MDSO), a leading global provider of cloud-based solutions for clinical research in life sciences. HealthPatch(R) MD can be used with Medidata's industry-leading technology platform (Medidata Clinical Cloud(R)) and its mobile app for patient-reported outcomes (Medidata Patient Cloud(R)) to further remote patient monitoring, which has the potential to make clinical trials more efficient.
MDSO: 47.27 (+0.15)

Insider Trading Alert - HAFC, PLCE And MDSO Traded By Insiders
at The Street - Mon Dec 08, 1:49PM CST
Stocks with insider trader activity include HAFC, PLCE and MDSO
HAFC: 21.70 (-0.07), MDSO: 47.27 (+0.15), PLCE: 56.74 (-1.02)

Veeva Stock Jumps After Q3 Earnings, Guidance Beat
at Investor's Business Daily - Wed Nov 26, 10:21AM CST
Shares of Veeva Systems (VEEV), a software provider to the life-science industry, jumped 9% in early trading in the stock market today after the company beat fiscal Q3 estimates and raised its guidance late Tuesday. Veeva's earnings for the quarter...
VEEV: 26.88 (+0.25), MDSO: 47.27 (+0.15), MDRX: 12.87 (-0.13), CERN: 65.10 (-0.21), ATHN: 149.72 (-1.78)

Medidata to Host Financial Analyst Day in New York City on December 8
Business Wire - Mon Nov 24, 7:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it will host a financial analyst day on Monday, December 8, 2014 in New York City. The executive management team will discuss Medidata's long-term growth strategy and showcase the company's innovative platform, the Medidata Clinical Cloud(R).
MDSO: 47.27 (+0.15)

Medidata and TransCelerate BioPharma Inc. Announce Findings of Joint Research Initiative on Clinical Trial Site Monitoring Methods
Business Wire - Wed Nov 19, 7:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the results of a data-driven analysis conducted in collaboration with TransCelerate BioPharma Inc. ("TransCelerate" , which assesses the value of source document verification (SDV) in a risk-based approach to clinical trial site monitoring. Published in the November edition of the Drug Information Association's Therapeutic Innovation & Regulatory Science (TIRS) journal, the results of the analysis support the TransCelerate-proposed methodology for risk-based monitoring (RBM), which can be adopted for different types, phases and stages of clinical trials.
MDSO: 47.27 (+0.15)

Medidata Collaborates with GlaxoSmithKline on Mobile Health Initiative to Test Novel Technology for Clinical Trial Optimization
Business Wire - Mon Nov 17, 2:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the completion of a method development project conducted in partnership with GlaxoSmithKline plc (GSK) to evaluate the impact of unifying mobile health (mHealth) devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs.
MDSO: 47.27 (+0.15), GSK: 42.85 (+0.11)

Investing in Socially Responsible Companies: Medidata Solutions Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Sun Nov 09, 7:10PM CST
Source: Medidata Solutions Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
MDSO: 47.27 (+0.15)

Medidata Teams up with Mundipharma Research to Move Clinical Research to the Cloud
Business Wire - Wed Nov 05, 7:30AM CST
Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology for clinical research in life sciences, today announced that Mundipharma Research Limited (Mundipharma) has adopted Medidata's cloud-based software platform to streamline and accelerate its drug development activities. As part of this agreement, Mundipharma will use the Medidata Clinical Cloud(R) software platform to capture clinical research data electronically and leverage the platform's analytics tools to enhance the speed and safety of its clinical trials.
MDSO: 47.27 (+0.15)

Medidata and PPD Partner to Offer New Approach to Risk-Based Monitoring
Business Wire - Tue Nov 04, 7:30AM CST
Medidata (NASDAQ:MDSO), a leading global provider of cloud-based solutions for clinical research in life sciences, and Pharmaceutical Product Development, LLC (PPD), a global contract research organization (CRO), today announced they are expanding their partnership to provide the life science industry with a more comprehensive approach to risk-based monitoring (RBM)--aimed at conducting drug development more intelligently, more quickly and more cost-effectively.
MDSO: 47.27 (+0.15)

Medidata Selected by ASLAN Pharmaceuticals as Enterprise-Wide Technology Platform for Enhancing Clinical Development
Business Wire - Thu Oct 30, 4:30PM CDT
Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it has signed an enterprise agreement with ASLAN Pharmaceuticals, an oncology-focused biotechnology company. ASLAN's adoption of the industry-leading Medidata Clinical Cloud(TM) supports the company's strategy of maximizing the value of its in-licensed drug portfolio by conducting high quality, efficient clinical development in Asia.
MDSO: 47.27 (+0.15)

Trade-Ideas: Medidata Solutions (MDSO) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Oct 29, 11:12AM CDT
Trade-Ideas LLC identified Medidata Solutions (MDSO) as a "dead cat bounce" (down big yesterday but up big today) candidate
MDSO: 47.27 (+0.15)

Medidata Solutions (MDSO) Stock Falls After Reporting Earnings
at The Street - Tue Oct 28, 2:55PM CDT
Medidata Solutions (MDSO) is falling Tuesday after missing analysts' estimates for revenue and lowering its full year guidance.
MDSO: 47.27 (+0.15)

Medidata Solutions' (MDSO) CEO Tarek Sherif on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 1:10PM CDT

MDSO: 47.27 (+0.15)

Medidata -8.5% on Q3 miss, full-year guidance cut
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:40AM CDT

MDSO: 47.27 (+0.15)

Medidata Solutions (MDSO) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 6:55AM CDT

MDSO: 47.27 (+0.15)

Medidata meets 3Q profit forecasts
Automated Insights - Tue Oct 28, 5:42AM CDT
NEW YORK (AP) _ Medidata Solutions Inc. (MDSO) on Tuesday reported third-quarter earnings of $161,000.
MDSO: 47.27 (+0.15)

Medidata Solutions misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 5:31AM CDT

MDSO: 47.27 (+0.15)

Medidata Reports Record Third Quarter 2014 Revenues
Business Wire - Tue Oct 28, 5:30AM CDT
--Record subscription revenue of $71.5 million, a 23% year-over-year increase
MDSO: 47.27 (+0.15)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 53

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 22

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 128

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading

Top 5 Most Recently Viewed Articles

InsCorp, Inc. Experiences Significant Growth Impact in 2025

Updated Category News Views 229

InsCorp, Inc. Sees Improved Financial Metrics in 2025 InsCorp, Inc. (OTCQX: IBTN) has announced results for the second quarter of 2025, demonstrating a noticeable upward trend in earnings per share (EPS) at $0.73, an increase from $0.57 in the prior quarter and $0.63 over the same period last year. Jim Rieniets, the President and CEO of INSBANK, expressed optimism about...

Continue Reading
Revance Celebrates National Sunscreen Day with Times Square Billboard

Updated Category News Views 223

Revance Celebrates National Sunscreen Day with a Bold Message Revance is thrilled to commemorate National Sunscreen Day with a vibrant digital billboard in Times Square. This event not only marks a celebration of Blue Lizard® Australian Sunscreen but also highlights the importance of sun safety as the summer season approaches. Blue Lizard is recognized as the leading...

Continue Reading
Exploring Noah Holdings' Strategic Vision for Global Growth

Updated Category News Views 523

Noah's Global Expansion and Innovative Services Noah Holdings has actively pushed the envelope in providing innovative financial services tailored to meet the diverse wealth management requirements of its clients. This year marks a significant chapter in their journey toward international expansion, where they are introducing groundbreaking solutions along with targeted...

Continue Reading
Streamline Your Taxes: Harness QuickBooks Reports Now

Updated Category News Views 21

QuickBooks: Not Just for Bookkeeping Anymore Taxes can be a pain, but if you're rocking QuickBooks, there's a silver lining. Karen Eberhart Metcalfe, the accounting whiz from Bolingbrook, IL, assures us that this tool isn't merely for ticking boxes in bookkeeping; it's your ace for navigating tax season with less sweat and more precision. When you’ve got those reports...

Continue Reading
Vistra's Options Trading Insights: What Big Investors Indicate

Updated Category News Views 177

Understanding Vistra's Options Trading Landscape Investors are closely observing the options trading activity for Vistra (NYSE: VST) as it indicates a notable bearish sentiment among significant traders. Retail traders would benefit from being aware of these trends. Current Market Sentiment Recent data revealed on options trading history highlights that a recognizable...

Continue Reading